Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Construction in Progress: 2021-2023

  • SAB Biotherapeutics' Construction in Progress was N/A to $329,617 in Q1 2023 from the same period last year, while for Mar 2023 it was $329,617, marking a year-over-year change of. This contributed to the annual value of $308,317 for FY2022, which is 93.31% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Construction in Progress of $329,617 as of Q1 2023, which was up 6.91% from $308,317 recorded in Q4 2022.
  • SAB Biotherapeutics' 5-year Construction in Progress high stood at $4.6 million for Q4 2021, and its period low was $308,317 during Q4 2022.
  • Over the past 3 years, SAB Biotherapeutics' median Construction in Progress value was $329,617 (recorded in 2023), while the average stood at $1.7 million.
  • Data for SAB Biotherapeutics' Construction in Progress shows a maximum YoY plummeted of 93.31% (in 2022) over the last 5 years.
  • Quarterly analysis of 3 years shows SAB Biotherapeutics' Construction in Progress stood at $4.6 million in 2021, then crashed by 93.31% to $308,317 in 2022, then reached $329,617 in 2023.
  • Its Construction in Progress stands at $329,617 for Q1 2023, versus $308,317 for Q4 2022 and $4.6 million for Q4 2021.